Hims & Hers stands out for personalized, compounded medications and consistent margin expansion but faces rising risks tied ...

With the recent approval in China of Innovent Biologics' (OTCPK:IVBIY) mazdutide as the first-ever dual GLP-1/glucagon receptor (GCP) for obesity, observers are already making comparisons of the drug ...

Hims & Hers Health continues to eye personalized services and global expansion. Read more on what investors should know about ...

These can include weight loss, loss of appetite, yellowing of the skin, vomiting or nausea, and the symptoms of diabetes ...

China has approved a new weight-loss drug that is poised to rival Novo Nordisk and Eli Lilly's popular GLP-1 treatments, ...

A new study has been launched into the side effects of weight loss and diabetes jabs after hundreds of cases of pancreatitis ...

These popular medications are now at the center of a major weight loss drug lawsuit. Find out which drugs and involved and ...

The MHRA has revealed it's received more than 560 reports of acute pancreatitis in patients taking GLP-1 injections since ...

Moderna disclosed that a study of 56,000 volunteers older than 50 found its new mRNA flu vaccine was more effective than an ...